A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)
Article in OncoImmunology (June 2024)
The most recent citing publications are shown below. View all 6 publications that cite this research output on Dimensions.
Article in OncoImmunology (June 2024)
Article in Molecular and Clinical Oncology (February 2024)
Article in Thoracic Cancer (February 2024)